Carmen Valcarce, Ph.D.

EVP, Chief Scientific Officer

Dr. Carmen Valcarce has over twenty years of experience in research and development; her research has primarily focused on diabetes and metabolic disorders. At vTv, Dr. Valcarce oversees the Preclinical Research, Quality Assurance, and Bioanalytical departments. Moreover, as the company’s diabetes expert, she is responsible for all ongoing research and development in the company’s diabetes programs. Additionally, Dr. Valcarce acts as the scientific liaison when in discussions with national and international regulatory agencies.

Dr. Valcarce joined vTv Therapeutics in 2007 to manage the company’s diabetes and metabolic disease research programs. Since then, she has held a series of leadership roles of increasing responsibility, including Senior Vice President of Preclinical Research (Pharmacology, DMPK, Toxicology and Pharmaceutical Development) where she was responsible for the preparation of 11 INDs which were all accepted by the FDA.

Prior to joining vTv, Dr. Valcarce spent 7 years at Novo Nordisk (Denmark) as the Project Leader and Scientific Coordinator for the Glucokinase Activator Project, which was in-licensed by vTv in 2007. Dr. Valcarce has been the key person in taking this project the whole way from idea to clinical development.

Dr. Valcarce holds a Ph.D. in Biochemistry and Molecular Biology from La Universidad Autonoma de Madrid (Spain) and holds the title of Docent in Experimental Clinical Chemistry at Lund University (Sweden). Additionally, she is the author of numerous papers and presentations and is an inventor of several patents and patent applications.